Congress Asset Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Congress Asset Management’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.51M	Buy	180,448 +1,893	+1%	+$34.3K	0.02%	264
2026 Q1	$3.33M	Buy	178,555 +107,459	+151%	+$1.78M	0.02%	271
2025 Q4	$937K	Sell	71,096 -2,269	-3%	-$26.8K	0.01%	315
2025 Q3	$526K	Buy	73,365 +514	+0.7%	+$26.8K	﹤0.01%	351
2025 Q2	$3.44M	Buy	72,851 +121	+0.2%	+$4.93K	0.02%	250
2025 Q1	$2.84M	Sell	72,730 -263	-0.4%	-$11.3K	0.02%	255
2024 Q4	$3.95M	Buy	72,993 +6,352	+10%	+$324K	0.03%	248
2024 Q3	$3.36M	Buy	+66,641	New	+$3.12M	0.02%	252

Other funds holding MLTX

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

TWD

True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Congress Asset Management's MLTX Position: Q2 2026 in Review

Congress Asset Management increased its MoonLake Immunotherapeutics (MLTX) stake by 1.1% in Q2 2026, buying an estimated $34.3K and bringing the position to 180,448 shares worth $3.51M. The position accounts for 0.02% of the portfolio, ranked #264.

Congress Asset Management first reported a position in MLTX in Q3 2024 and has held it in 8 quarters since. The position peaked at $3.95M in Q4 2024. 6 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

Congress Asset Management held 180,448 shares of MoonLake Immunotherapeutics worth $3.51M as of Q2 2026.
Congress Asset Management bought 1,893 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $34.3K.
MoonLake Immunotherapeutics made up 0.02% of Congress Asset Management's portfolio in Q2 2026, its #264 holding.
Congress Asset Management first reported a position in MoonLake Immunotherapeutics in Q3 2024 and has held it in 8 quarters since.
Congress Asset Management's MoonLake Immunotherapeutics position peaked at $3.95M in Q4 2024.
6 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Congress Asset Management's 13F filing for Q2 2026, filed 7 Jul 2026.